Innate Pharma SA (IPH) A EUR0.05

Sell:€1.97Buy:€2.01€0.01 (0.40%)

Prices delayed by at least 15 minutes
Sell:€1.97
Buy:€2.01
Change:€0.01 (0.40%)
Deal now
Prices delayed by at least 15 minutes
Sell:€1.97
Buy:€2.01
Change:€0.01 (0.40%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Key people

Irina Staatz-Granzer
Chairwoman of the Board of Directors
Jonathan Elliot Dickinson
Chief Executive Officer, Member of the Leadership Team
Pascale Boissel
Independent Vice Chairwoman of the Supervisory Board
Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Yannis Morel
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team
Sonia Quaratino
Executive Vice President, Member of the Executive Board, Chief Medical Officer, Member of the Leadership Team
Eric Vivier
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Odile Laurent
Vice President - Human Resources, Member of the Leadership Team
Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Claire de Saint-Blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Sally Bennett
Independent Member of the Supervisory Board
Jean-Yves Blay
Independent Member of the Supervisory Board
Veronique Chabernaud
Independent Member of the Supervisory Board
Gilles Brisson
Member of the Supervisory Board
Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Click to see more

Key facts

  • EPIC
    IPH
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FR0010331421
  • Market cap
    €182.69m
  • Employees
    168
  • Shares in issue
    83.83m
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.